About kaleido biosciences inc - KLDO
Kaleido Biosciences, Inc. is a clinical-stage healthcare company, which engages in the provision of healthcare services. It focuses on leveraging the microbiome organ to treat disease and improve human health. The firm offers microbiome metabolic therapies (MMT), which are designed to modulate the metabolic output and profile of the microbiome by driving the function and composition of the organ's existing microbes. The company was founded by Geoffrey von Maltzahn and Noubar B. Afeyan on January 27, 2015 and is headquartered in Lexington, MA.
KLDO At a Glance
Kaleido Biosciences, Inc.
65 Hayden Avenue
Lexington, Massachusetts 02421
| Phone | 1-617-674-9000 | Revenue | 1.10M | |
| Industry | Pharmaceuticals: Major | Net Income | -90,288,000.00 | |
| Sector | Health Technology | 2021 Sales Growth | 13.231% | |
| Fiscal Year-end | 12 / 2022 | Employees | 76 | |
| View SEC Filings |
KLDO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 90.621 |
| Price to Book Ratio | 9.598 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.976 |
| Enterprise Value to Sales | 75.422 |
| Total Debt to Enterprise Value | 0.261 |
KLDO Efficiency
| Revenue/Employee | 14,526.316 |
| Income Per Employee | -1,188,000.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.02 |
KLDO Liquidity
| Current Ratio | 1.425 |
| Quick Ratio | 1.425 |
| Cash Ratio | 1.296 |
KLDO Profitability
| Gross Margin | -113.587 |
| Operating Margin | -7,940.851 |
| Pretax Margin | -8,178.261 |
| Net Margin | -8,178.261 |
| Return on Assets | -164.248 |
| Return on Equity | -580.574 |
| Return on Total Capital | -279.521 |
| Return on Invested Capital | -328.153 |
KLDO Capital Structure
| Total Debt to Total Equity | 204.525 |
| Total Debt to Total Capital | 67.162 |
| Total Debt to Total Assets | 43.115 |
| Long-Term Debt to Equity | 52.324 |
| Long-Term Debt to Total Capital | 17.182 |